(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of 25.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Fulcrum Therapeutics's revenue in 2025 is $80,000,000.On average, 1 Wall Street analysts forecast FULC's revenue for 2028 to be $582,976,505, with the lowest FULC revenue forecast at $582,976,505, and the highest FULC revenue forecast at $582,976,505. On average, 1 Wall Street analysts forecast FULC's revenue for 2029 to be $1,209,676,247, with the lowest FULC revenue forecast at $1,209,676,247, and the highest FULC revenue forecast at $1,209,676,247.
In 2030, FULC is forecast to generate $2,542,965,106 in revenue, with the lowest revenue forecast at $2,542,965,106 and the highest revenue forecast at $2,542,965,106.